We are excited to share that Alan Landay, PhD, has joined UTMB as Vice
President of Team Science, effective Feb. 1. In this role, he will bring
research and clinical experts together to create collaborations at UTMB and
with institutions across the region, state, and world. He also serves as
Professor in the Departments of Internal Medicine and Microbiology &
Immunology.
Dr. Landay most recently served Rush University as Vice Chair of Research
and Division Chief of Translational and Precision Medicine in the Department of
Internal Medicine.
Dr. Landay has been involved in HIV research for more than 42 years, having
performed some of the first immune evaluations of HIV-infected hemophiliacs in
1981. With Abbott Labs he helped develop the first HIV antibody test licensed
by the FDA in 1985 for use in screening the blood supply. His laboratory has
made important original contributions in understanding the role of immune
activation and inflammation in outcomes of non-communicable disease related to
aging in the HIV population.
For more than 30 years Dr. Landay has been an investigator for the Advancing
Clinical Therapeutics Network (ACTG), a global clinical trials network that
conducts research to improve the management of HIV and its comorbidities;
develop a cure for HIV; and innovate treatments for tuberculosis, hepatitis C,
and emerging infectious diseases. Since its inception 20 years ago, he has led
the Rush Immunology Support Lab.
Dr. Landay has extensive experience in aging-related studies. For the past
10 years, his research focus has been on studies of the human microbiome and
metabolome and better understanding its role both in health and disease. More
recently, Dr. Landay led the research effort for COVID-19 in the Department of
Medicine at Rush, leading the establishment of the COVID-19 biorepository. He
also leads the COVID-19 lab efforts for the NIH-funded ACTG Lab group.
Additionally, he has extensive experience over the past 10 years working with
laboratories in international settings in his role as Scientific Director of
Labs for the NIH-funded ACTG Grant.
We are
thrilled to have Dr. Landay on board. His expertise and experience will be
critical to our ongoing endeavor to advance collaboration, innovation, and
breakthrough science within our Research Enterprise.
Many thanks,
Charles P. Mouton, MD, MS, MBA
Executive Vice President, Provost, and Dean, John Sealy School of Medicine
Thomas N. and Gleaves P. James Distinguished Chair
Randall J. Urban, MD
Vice President and Chief Research Officer
Vice Dean, Clinical Research, John Sealy School of Medicine